Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Capricor Therapeutics (CAPR) Tops Q3 EPS by 27c
November 7, 2019 4:50 PM ESTCapricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.43), $0.27 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $142.1 thousand versus the consensus estimate of $200 thousand.
As of September 30, 2019, the Companys cash, cash equivalents and marketable securities totaled approximately $6.8 million compared to approximately... More
